Education
About Us
Working with TipRanks
Follow Us
Pyxis Oncology (PYXS)
NASDAQ:PYXS
PYXS Stock Chart & Stats
$3.23
-$0.10(-5.75%)
At close: 4:00 PM EST
$3.23
-$0.10(-5.75%)
Day’s Range― - ―
52-Week Range$0.83 - $5.39
Previous CloseN/A
Volume258.73K
Average Volume (3M)920.23K
Market Cap
$229.47M
Enterprise Value-$2.84M
Total Cash (Recent Filing)$88.94M
Total Debt (Recent Filing)$19.46M
Price to Earnings (P/E)―
Beta1.15
Next Earnings
Nov 18, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding62,018,135
10 Day Avg. Volume1,030,172
30 Day Avg. Volume920,230
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-0.01
Enterprise Value/Revenue-0.46
Enterprise Value/Gross Profit-0.88
Enterprise Value/Ebitda0.03
Forecast
1Y Price Target
$6.25Price Target Upside93.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentMICVO's early HNSCC efficacy signal from the phase 1 dose escalation, if replicated, would be strongly competitive clinical data and supportive of late-stage development.
Financial PerformancePyxis Oncology, Inc. reported milestone revenue of $2.8M, marking a positive financial development compared to no revenues previously.
Strategic InitiativesThe company plans to develop MICVO for head and neck squamous cell carcinoma patients and other solid tumors, indicating a strategic expansion in their treatment pipeline.
Bears Say
Data TimelinePreliminary data for 2/3L monotherapy in PD-1 and EGFR targeted therapy experienced patients are not expected until the first half of 2026, indicating a delay in the data timeline.
Financial ChallengesThe company reported a net loss of $0.30 per diluted share, which is an improvement but still indicates financial challenges.
Market CompetitionSeveral ADCs studied in this setting have been discontinued because they matched the short benefit, but also added additional toxicities driven by on-target, off-tumor cell killing.
Pyxis Oncology News
PYXS FAQ
What was Pyxis Oncology’s price range in the past 12 months?
Pyxis Oncology lowest stock price was $0.83 and its highest was $5.39 in the past 12 months.
What is Pyxis Oncology’s market cap?
Pyxis Oncology’s market cap is $229.47M.
When is Pyxis Oncology’s upcoming earnings report date?
Pyxis Oncology’s upcoming earnings report date is Nov 18, 2025 which is in 34 days.
How were Pyxis Oncology’s earnings last quarter?
Pyxis Oncology released its earnings results on Aug 14, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.352 by $0.052.
Is Pyxis Oncology overvalued?
According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued.
Does Pyxis Oncology pay dividends?
Pyxis Oncology does not currently pay dividends.
What is Pyxis Oncology’s EPS estimate?
Pyxis Oncology’s EPS estimate is -0.34.
How many shares outstanding does Pyxis Oncology have?
Pyxis Oncology has 62,018,135 shares outstanding.
What happened to Pyxis Oncology’s price movement after its last earnings report?
Pyxis Oncology reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.352. Following the earnings report the stock price went up 8.85%.
Which hedge fund is a major shareholder of Pyxis Oncology?
Currently, no hedge funds are holding shares in PYXS
Pyxis Oncology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.25 (93.50% Upside)
$6.25 (93.50% Upside)
Blogger Sentiment
Bullish
PYXS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 218.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 16.8%
Last 30 Days ▲ 16.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.81%
12-Months-Change
Fundamentals
Return on Equity
-74.80%
Trailing 12-Months
Asset Growth
-40.87%
Trailing 12-Months
Company Description
Pyxis Oncology
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
PYXS Stock 12 Month Forecast
Average Price Target
$6.25
▲(93.50% Upside)
Technical Analysis
Nkarta
―
Greenwich LifeSciences
―
Elicio Therapeutics
―
Biomea Fusion
―
Nuvectis Pharma
―
Ownership Overview
10.30% Insiders
5.94% Mutual Funds
26.29% Other Institutional Investors
53.84% Public Companies and
Individual Investors